I'm more interested in how your "Celgene put" is looking, but it is really quite simple Madame.....in Japan, around 4000 transplants take place annually, of which just half incur GvHD. With an estimated cost of over $US100k per treatment, a 20% royalty for even 25% of the cases would make for a "commercial success." This of course is just 1 application in 1 market and this number would grow sharply as full approval would widen the scope for use in related diseases such as Crohn's. Oh and thanks for defining quantum for me...most useful.
I'm more interested in how your "Celgene put" is looking, but it...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.030(3.13%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 96.5¢ | $1.03 | 96.5¢ | $4.704M | 4.708M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 87395 | 98.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 274051 | 2 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |